

mains.

**Edient: Sterile ceftriaxone sodium equivalent to 0.5 g/1 g/2 g of cetains 3.6 mmol of sodium per gram of ceftriaxone.

Nosage and administration

Sosage and administration

Sosage and administration

dulits and children over 12 years old:

the usual coages in 2: 2 of Lebacef, administered once daily (every 24 hours).

severe cases or in infections caused by only moderately sensitive organisms, the dosage may be raised to 4 g administered once daily.

the following dosage guidelines are recommended for once-daily administration.

Recontates (a pto 1 of days): A daily dose of 20-50 mpkg bodyweight. 50 mpkg should not be exceeded.

Is not necessary to differentiate between premature infinist and dhose born at term.

Interest and children (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and children (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and children (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and children (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and children (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and children (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and children (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and children (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and children (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and children (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and term (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and term (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and term (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and term (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and term (15 days to 72 years): A daily dose of 20-50 mpkg.

Interest and term (15 days to 72 days 10 years)

Interest and term (15 days to 72 days 10 years)

Interest and term (15 days 10 years)

Interest and (15 d

maximum of 2 g in children a ng and non-penicillinase pro

Verified the constructions and those use extractions are puresolutions should only be used for international rejection.

The grant of Lebesch contains approximately 3.6 mmol sodium. To be taken into consideration by patients on a controlled sodium diregnancy centruscore consesse the patiental barrier. No controlled clinical studies are available.

Those properties of the controlled clinical studies are available, and the controlled clinical studies are available.

The controlled properties are consessed the patiental barrier. No controlled clinical studies are available, and the controlled clinical studies. Lebesch should only be used in pregnitorially with the first time months, if there is a compelling indicator for its use.

Lebesch are controlled to the controlled controlled controlled to the controlled controlled controlled controlled to the controlled contro

ire intoxing undestrable effects, which subsided either spontaneously or after withdrawal of the drug, have been observed during of defibiasone:
Infections: Eleze: mycosis of the genital tract, superinfection with non-susceptible organisms.
Infections: Eleze: mycosis of the genital tract, superinfection with non-susceptible organisms.
Below and impulsed system: Common; cosinophila, leukerin, granulocytosis, etc.)
Below and prompting system: Common; cosinophila, leukerin, granulocytosis, etc.
Below and prompting systems: a superinferent system of the prompting tractions of the prompting tractions and the prompting tractions are the analysis of the prompting tractions and the prompting tractions of the prompting tractions are the analysis of the prompting tractions and the prompting tractions are the prompting tractions of the prompting tractions o

Softe: Controller, one: a seeing real mission, portion, policial in centra, very rate. Invested an inscion of Kindlergs and unimary tract. Base: objective, levy rare revise proportions have been exported, mostly treated with either high disky doses (e.g. 280 mg/kg/glay) or total doses in soccess of 10 g and with treated with either high disky doses (e.g. 280 mg/kg/glay) or total doses in soccess of 10 g and with remarks upon discontinuation of Laborator and the control of the c

Overdosage Excessive plasma

were observed in an in vitro study of celtrisance in combination with chorampherical.

harmacodynamics
harmaco

harmacoxinetics
permanetarises of centrol continuous
permanetarises of centrol
permanetarises

Intervenos administration certainse of certain the service of the

Ceftriaxone penetrates the inflamed meninges of neonates, infants and children.

The average concentration in CSF during bacterial meningitis is 17% of the plasma concentration; in aseptic meningitis it is 4%. 24 hours

The average concentration in CSF during bacterial meningitis is 17% of the plasma concentration; in aseptic meningitis it is 4%, 24 hours after I.V. injection of Lebacef in doses of 50-100 mg/kg bodyweight, ceftriaxone concentrations > 1.4 mg/l were measured in CSF. In adult patients with meningitis, administration of 50 mg/kg leads within 2-24 hours to CSF concentrations several times higher than the

minimum inhibitory concentrations required for the most common causative organisms of meningitis.

Metabolism: Ceftriaxona is not metabolized in the organism itself. Only following billary excretion into the intestinal lumen does the intestinal flora transform the active ingredient into inactive metabolities.

initial anisotrin the acute ingredient into inactive meabonies.

Elimination: Plasma clearance is 10-22 mil/min. Renal clearance is 5-12 mil/min. 50-60% of ceftriaxone is excreted unchanged via the kidneys, while 40-50% is excreted unchanged in the hile. The plasma half-life in adults is about 8 hours.

Pharmacokinetics in special patient groups: In neonates, renal elimination accounts for about 70% of the dose.

In infants aged less than 8 days and in persons aged over 75 years, the average plasma half-life is approximately 2-3 times that in healthy

young adults.

In patients with mild to moderate renal failure or hepatic dysfunction, the pharmacokinetics of ceftriaxone are only slightly altered. The

plasma half-life is minimally increased. If kidney function alone is impaired, billary elimination of ceftriaxone is increased, whereas if liver function alone is impaired, renal elimination is increased.

Presentation

Lebsed 0.5 g for I.M. injection:

OPAT Kir. 1 vial containing sterile powder of ceftriaxone sodium equivalent to 0.5 g of ceftriaxone, 1 solvent ampoule containing 2 ml lidocaine solution (fidocaine hydrochloride 1%), sterile syringe, 2 needles, sterile alcohol swab, adhesive bandage.

Lebacef 0.5 g for i.V. injection:

OPAT Kit: T vial containing sterile powder of ceftriaxone sodium equivalent to 0.5 g of ceftriaxone, 1 solvent ampoule containing 5 ml water for injection, sterile syringe, 2 needles, sterile alcohol swab, adhesive bandage.

Lebacef 0.5 g for I.M./I.V. injection:
Pack of 10 vials each containing sterile powder of ceftriaxone sodium equivalent to 0.5 g of ceftriaxone.

Lebacef 1 g for I.M. injection:

OPAT Kit: 1 vial containing sterile powder of ceftriaxone sodium equivalent to 1 g of ceftriaxone, 1 solvent ampoule containing 3.5 ml

lidocaine solution (lidocaine hydrochloride 1%), sterile syringe, 2 needles, sterile alcohol swab, adhesive bandage.

Lebacef 1 g for I.V. injection:

OPAT XIET 1 vital containing sterile powder of ceftriaxone sodium equivalent to 1 g of ceftriaxone, 1 solvent ampoule containing 10 ml water

for injection, sterile syringe, 2 needles, sterile alcohol swab, adhesive bandage.

Lebacef 1 g for I.M.IV. Injection:

Pack of 10 visile seach containing sterile powder of ceftriaxone sodium equivalent to 1 g of ceftriaxone.

Lebacef 2 g for I.V. Infusion:
Pack of 1 or 10 vials each containing sterile powder of ceftriaxone sodium equivalent to 2 g of ceftriaxone.

Expiry date and storage conditions

See the expiry date printed on the outer carton.

This date refers to the product correctly stored in unopened package.

Beware not to use Lebacef after this date.

Store below 30°C. Protect from light and heat.
Keep all medicines out of reach of children

Manufactured by: Mitim S.R.L.

For:

Brescia Italy

APWAN Pharmaceutical Industries Lebanon e a L

Jadra, Lebanon THIS IS A MEDICAMENT

Medicament is a product which affects your health, and its consumption contrary to instructions is dangerous for you.

Council of Arah Health Ministers | Union of Arah Pharmaciete

- Follow strictly the doctor's prescription, the method of use and the instructions of the pharmacist who sold the medicament.
- The doctor and the pharmacist are experts in medicines, their benefits and risks.
 Do not by yourself interrupt the period of treatment prescribed for you.
- Do not repeat the same prescription without consulting your doctor.

Keep all medicaments out of the reach of children.